China Revokes Licenses For Shanghai Hualian Leukemia Drugs Found Contaminated (China)
This article was originally published in PharmAsia News
Executive Summary
China revoked the license of Shanghai Hualian Pharmaceutical in the wake of an investigation that found it was marketing contaminated leukemia drugs that harmed patients. The company's license was canceled and the employees responsible have been detained, according to the State FDA. The agency accused the employees of a "systematically organized" cover-up during the government investigation of a case of several children injected with methotrexate who developed leg pains and difficulty walking. Use of the drug and another based on cytarabin hydrochloride were ordered suspended in September. The parent company, Shanghai Pharmaceutical Group, was ordered to compensate the families of the patients. (Click here for more ) "Cancer Drug Company Slammed After Probe" Shanghai Daily (China) (12/13/07)
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.